UnknownPhase 2

Dose-Ranging Study of an Ophthalamic Solution in Patients With Loss of Visual Function Due to Age-Related Nuclear Cataract

Nepal81 participantsStarted 2007-11

Plain-language summary

This study will evaluate the safety and efficacy of three doses of C-KAD Ophthalmic Solution in patients with loss of visual function due to age-related nuclear cataract

Who can participate

Age range35 Years – 90 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Presence of nuclear sclerosis cataract * BCDVA within the range of 20/40 and 20/80 Exclusion Criteria: * Any other clinical condition in the eye that may compromise vision * Presence or history of glaucoma * Presence or history of diabetes * Use of eyedrops * Use of steroids

What they're measuring

Best-corrected visual acuity by ETDRS

Timeframe: 360 days

Trial details

NCT IDNCT00825721

SponsorChakshu Research, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2009-08

View on ClinicalTrials.gov More Nuclear Cataract trials